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Abstract  
Arachidonic acid (AA) and its oxygenated derivatives, collectively known as the 
eicosanoids, are key mediators of a wide variety of physiological and pathophysiological 
states. AA, obtained from the diet or synthesized from linoleic acid, is rapidly 
incorporated into cellular phospholipids by the concerted action of arachidonoyl-CoA 
synthetase and lysophospholipid acyl transferases. Under the appropriate conditions, AA 
is liberated from its phospholipid storage sites by the action of one or various 
phospholipase A2 enzymes. Thus, cellular availability of AA, and hence the amount of 
eicosanoids produced, depends on an exquisite balance between phospholipid reacylation 
and hydrolysis reactions. This review focus on the enzyme families that are involved in 
these reactions in resting and stimulated cells.  
 
 
Abbreviations 
AA, arachidonic acid;  ACS, acyl-CoA synthetase;  PA, phosphatidic acid; PC, choline 
glycerophospholipids; PE, ethanolamine glycerophospholipids, PI, phosphatidylinositol; 
PIP2; phosphatidylinositol 4,5-bisphosphate; PS, phosphatidylserine; PG, 
phosphatidylglycerol; PLA2, phospholipase A2; cPLA2α, group IVA cytosolic 
phospholipase A2α; iPLA2, calcium-independent phospholipase A2; iPLA2-VIA, group 
VIA calcium-independent phospholipase A2; sPLA2, secreted phospholipase A2; LPAAT, 
lysoPA:acyl-CoA acyltransferase; LPCAT, lysoPC:acyl-CoA acyltransferase; LPEAT, 
lysoPE:acyl-CoA acyltransferase; LPIAT, lysoPI:acyl-CoA acyltransferase; MBOAT, 
membrane bound O-acyltransferase; AGPAT, acyl glycerol phosphate acyltransferase. 
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1. Introduction 
Arachidonic acid (5,8,11,14-eicosatetraenoic acid, ω-6) (AA) is an essential fatty acid 
that is obtained directly from dietary sources or indirectly, from conversion of linoleic 
acid. AA is the precursor of a large family of bioactive compounds called the 
eicosanoids, produced by oxygenation through cyclooxygenase and lipoxygenase 
pathways [1, 2]. Because of the potent biological actions of the eicosanoids  cells keep 
this fatty acid at very low levels, by promoting its esterification into cellular lipids. As a 
matter of fact the availability of free AA is well described to constitute a rate-limiting 
step in the generation of eicosanoids by mammalian cells [3, 4]. In addition, free AA may 
also exert signaling functions by itself, e.g. as an inducer of apoptosis [5]. 
Under physiological conditions, AA is generally found esterified into the sn-2 
position of glycerophospholipids, particularly choline glycerophospholipids (PC) 
ethanolamine glycerophospholipids (PE), and phosphatidylinositol (PI). The production 
of free AA is a highly regulated process that represents a balance between two competing 
reactions, namely, phospholipid deacylation by phospholipase A2 (PLA2) enzymes, and 
reacylation and transfer into various phospholipid pools by acyltransferases and 
transacylases [6]. Depending on the state of the cell (i.e. resting or activated) one kind of 
reaction will dominate over the other. Thus in resting cells reacylation dominates, and 
hence, the bulk of cellular AA is found in esterified form. In stimulated cells, the 
dominant reaction is the PLA2-mediated deacylation, which results in dramatic releases 
of free AA that is now available for eicosanoid synthesis. However, under activation 
conditions AA reacylation is still very significant, as manifested by the fact that only a 
minor fraction of the AA released by PLA2 is available for eicosanoid synthesis, and the 
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remainder is effectively incorporated back into phospholipids by acyltransferases [5, 6]. 
In this regard, various studies have shown that the rate of AA incorporation into cellular 
phospholipids is slightly increased following cellular stimulation [7-11]. Such an increase 
is generally thought to be important for the replenishment of the intracellular pools of AA 
being exhausted as a  result of cellular stimulation [6]. However, increased influx of 
exogenous AA into phospholipids can also occur under conditions where no endogenous 
AA release occurs [12, 13], implying that this may actually be an independent process. 
 
2. Regulation of AA Incorporation into Phospholipids 
The pathways for AA incorporation into various classes of glycerophospholipids have 
been described in detail in various cells, particularly those involved in inflammatory 
reactions such as neutrophils and macrophages [6, 14]. Two distinct pathways appear to 
exist for the initial incorporation of AA. (Fig. 1) The first one is a high affinity pathway 
that incorporates low concentrations of AA into phospholipids via direct acylation 
reactions catalyzed by coenzyme A-dependent acyltransferases. This is thought to be the 
major pathway for AA incorporation into phospholipids under physiological conditions 
[6]; thus the PLA2-dependent availability of lysophospholipid acceptors may constitute a 
critical regulatory factor [15, 16]. The second pathway operates under high levels of free 
AA, which may be pathophysiological, and leads to the incorporation of the fatty acid 
primarily via the de novo route for phospholipid biosynthesis, resulting ultimately in the 
accumulation of AA into triacylglycerols and diarachidonoyl phospholipids [6]. This 
“high-capacity, low affinity” pathway is thought to primarily operate after the high-
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affinity deacylation/reacylation pathway has been saturated due to the high AA 
concentrations [6]. 
Once the AA has been incorporated into phospholipids, a remodeling process 
carried out by CoA-independent transacylase transfers AA from choline 
glycerophospholipids (PC) to ethanolamine glycerophospholipids (PE), in a  process that 
generally takes several hours in primary cells but is strikingly fast in tumor cell lines,  
where it takes only minutes [17-20]. In inflammatory cells, a major consequence of the 
CoA-independent transacylase-driven remodeling reactions is that, despite PC being the 
preferred acceptor for exogenous AA, under equilibrium conditions AA is more abundant 
in PE than in PC [6, 14].  
 
2.1. Lysophospholipid regulation of AA incorporation 
For the efficient incorporation of AA into phospholipids, two kinds of lysophospholipid 
acceptors should be readily available in the cell. Lysophospholipids, particularly lysoPC, 
are needed for the initial incorporation of AA into phospholipids via the Lands pathway, 
and lysophospholipids are again required, particularly lysoPE, for AA remodeling 
between phospholipids via CoA-independent transacylation reactions (Figure 2) [15]. 
Given that AA preferentially incorporates into the sn-2 position of phospholipids, the 
lysophospholipid acceptors used for AA incorporation and remodeling are of the 2-lyso 
type, i.e. those produced by PLA2s.  
It is likely that several PLA2 forms may contribute to the 2-lysophospholipid pool 
utilized for AA incorporation and remodeling and that their identity varies between cell 
types and tissues. In phagocytic cells, a significant part of the steady-state level of lysoPC 
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appears to be maintained by the continuing action of Ca2+-independent Group VIA 
phospholipase A2 (iPLA2-VIA) on cellular phospholipids [21, 22]. Thus, a decrease in the 
activity of the iPLA2–VIA frequently results in the diminished production of lysoPC and 
hence in the inhibition of AA incorporation into phospholipids [21, 22] 
Earlier studies on the initial incorporation of AA into glycerophospholipids in 
mouse macrophages indicated that the process was essentially Ca2+-independent [12], 
suggesting that the PLA2 putatively responsible for generating lysophospholipid 
acceptors for AA incorporation would correspond to that of an iPLA2-like enzyme [12]. 
Such an activity was later identified to belong to iPLA2–VIA in studies carried out with 
murine P388D1 macrophage-like cells [23, 24]. However, evidence has also been 
provided to indicate that iPLA2-VIA does not serve this function in other cell types [25], 
suggesting that, like other iPLA2-regulated processes, the involvement of iPLA2-VIA in  
phospholipid AA incorporation may depend on cell type and, in particular, on the 
expression level of iPLA2-VIA (i.e. how much the enzyme contributes to the steady-state 
lysophospholipid pool of a given cell). Based on studies of iPLA2 inhibition by the 
inhibitor bromoenol lactone (BEL), the iPLA2–VIA contribution ranges from  ~90% in 
rat submandibular ductal cells [26], to 50-60% in phagocytic cells [16, 23, 24, 27-30], 
and to only 20-25% in rat uterine stromal cells [31]. Studies in rat pancreatic islets, where 
iPLA2 inhibition by BEL does not result in diminished AA incorporation into 
phospholipids [25], have estimated that iPLA2-VIA contributes to at least 20% of the 
steady-state lysophospholipid levels of these cells. Given that rat pancreatic islets 
maintain cellular lysophospholipid levels at  high levels, it seems possible that the 
amount of lysophospholipid present in these cells  even after iPLA2 inhibition by BEL is 
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still high enough to account for a normal rate of AA incorporation into phospholipids. In 
agreement with this view, studies on AA incorporation utilizing cells overexpressing 
iPLA2–VIA have indicated that the excess amount of lysophospholipid produced under 
those conditions does not increase the rate of fatty acid incorporation [16, 32, 33].  
On the other hand, we believe that it is important to note that a slowed rate of AA 
incorporation into phospholipids due to diminished availability of lyso acceptors 
subsequent to iPLA2 inhibition, does not necessarily imply that the profile or amount of 
AA-containing phospholipids may have to change under equilibrium conditions, as has 
been assumed in a number of papers. The distribution of AA among phospholipid classes 
ultimately depends on transacylation reactions that are essentially iPLA2-independent, 
and do not change whether iPLA2 is inhibited or not (see below). 
Very few studies have focused on the PLA2 enzyme providing lysophospholipid 
acceptors for AA remodeling reactions via CoA-independent transacylases. The nature of 
such a PLA2 has been investigated in peripheral T lymphocytes [13] and U937 
macrophages [15] by measuring the transfer of AA from PC to PE in the presence of 
different PLA2 inhibitors. Inhibitors of group IVA cytosolic phospholipase A2α 
(cPLA2α), and iPLA2-VIA failed to exert any detectable effect on the transfer of AA 
from PE to PC in either cell type,  raising the possibility that the PLA2 implicated in this 
pathway might be an as yet undefined PLA2. The Ca2+-independent nature of the 
response suggests the involvement of an iPLA2-like activity different from the group VIA 
enzyme. An iPLA2 activity that is not inhibted by BEL and therefore is not a group VI 
enzyme, was recently identified in U937 macrophage-like cells [15, 34]. This activity 
appears to prefer PE as substrate, consistent with a presumed role in providing lysoPE 
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acceptors for transacylation reactions [15].  
 
2.2. Acyl-CoA synthetases utilizing AA 
The first enzymatic step for the incorporation of AA into phospholipids is catalyzed by 
the enzyme acyl-CoA synthetase (ACS), which activates the carboxyl group of AA by 
coupling a CoA moiety to it via a thioester linkage.  
All enzymatically active ACSs contain at least two conserved amino acid 
sequence domains: a covalent AMP-binding domain (motif I) consisting of 10 residues 
highly conserved from bacteria to humans [35] and a 36-37-residue domain (motif II) 
containing a sequence that is thought to be essential for binding of the substrate [36]. The 
latter has been used to assign ACSs to subfamilies [35, 36]. Up to now, 26 different ACS 
isoforms, each encoded by a separate gene, have been identified in the genome of human 
cells [36], although 4 of them are still considered as candidates to exhibit ACS activity 
based on the presence of the two distinctive motifs (medium-chain ACS-2A, short-chain 
ACS-3, medium-chain ACS-5, and ACS family-4). Twenty-two of these ACSs are 
classified into 5 subfamilies considering the chain length of the fatty acid of their 
preferred acyl groups (short-chain ACSs, medium-chain ACSs, long-chain ACSs, very 
long-chain ACSs and “bubblegum” ACSs); the other four proteins do not belong to any 
subfamily and are denominated ACSF (ACS family) (Table 1). The ACS enzymes 
displaying some preference for AA are typically those of the ACSL family. Thus, a 
summary of the properties of the other ACS families is given below and the long-chain 
acyl-coenzyme A synthetase (ACSL) family is reviewed in more detail. 
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The family of short-chain acyl-coenzyme A synthetases (ACSs) are composed by 
three enzymes (ACSS1, 2 and 3) capable of activating acetate, propionate or butyrate. It 
has been described in bovine, murine and human tissues that this family uses mainly 
acetate as a substrate, presenting a weak selectivity for propionate or butyrate [37, 38].  
The medium-chain acyl-coenzyme A synthetase family (ACSMs) consists of six 
enzymes, all localized almost exclusively in the mitochondrial matrix. These ACSs 
activate C4-10 fatty acids, although the selectivity can drastically differ between each 
isoform [39]. The metabolism of medium-chain fatty acids is poorly understood, but it is 
thought to play an important role in energy generation, given that the medium-chain fatty 
acids are probably generated from long- and very-long fatty acids by peroxisomal β-
oxidation, and  further degradation via mitochondrial β-oxidation after transportation into 
the mitochondrial matrix. [40]. 
The very long-chain acyl-coenzyme A synthetase family (ACSVLs) is composed 
of six membrane integral proteins (ACSVL-1 to -6) that are capable of activating long-
chain, branched-chain and very long-chain fatty acids containing more than 22 carbons. 
Members of this family are also designated as fatty acid transporter proteins (FATPs), 
and are thought to be involved in translocation of long- and very long-chain fatty acids 
across the plasma membrane [41]. Thus, these proteins could play a dual role in the 
transport and esterification of their substrates, with the exception of ACSVL3/FATP3, 
which has been demonstrated not to exhibit fatty acid transport activity [42].  
The first member of the “bubblegum” acyl-coenzyme A synthetases (ACSBGs) 
were originally discovered in the Drosophila mutant “bubblegum”, characterized by 
neurodegeneration and high tissue levels of saturated very long-chain fatty acids [43]. 
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Overexpression of human ACSBG1 led to the finding that this enzyme activates both 
long- and very long-chain fatty acids [35]. More recently, a second member (ACSBG2) 
has been located in murine and human testis and brainstem, showing a high degree of 
homology to ACSBG1 [44]. 
The long-chain acyl-coenzyme A synthetases (ACSLs) are the best characterized 
of the ACS families and play a key role in remodeling of membranes and de novo lipid 
synthesis. To date, five ACSL isoforms have been described in mammalian cells, 
ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6 [45], with at least two spliced transcript 
variants per isoform. Based on sequence homologies, the ACSL enzymes have been 
subdivided into two major groups, ACSL1/ACSL5/ACSL6 and ACSL3/ACSL4 [46]. 
ACSL1 was the first cloned human ACSL family gene [47]. Originally it was considered 
to be different from ACSL2 [48], but later it was found to be the same gene, which went 
on to be denominated ACSL1. As a consequence, the rat ACS2 gene was renamed Acsl6, 
because of its high homology with human ACSL6. A remarkable characteristic of 
ACSL1 is that the rodent protein is one residue longer than the human protein (699 and 
698 amino acids, respectively). This enzyme is predominantly located in heart, liver and 
adipose tissue and uses a wide range of fatty acids, although with a slight preference for 
palmitic, oleic, and linoleic acids [49].  
ACSL3 is one of two ACSL isoforms highly expressed in brain [50, 51]. It is 
located in the endoplasmic reticulum and lipid droplets [52]. ACSL3 presents a marked 
selectivity for AA and eicosapentaenoic acid over other unsaturated fatty acids, although 
its preference also for myristic acid and lauric acid makes this isoform less specific than 
ACSL4 with regard to AA and eicosapentaenoic acid.  
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ACSL4 shows close homology to ACSL3, sharing 68% of their amino acids. It is 
expressed predominantly in steroidogenic tissue and located in peroxisomes and 
mitochondrial membrane. With regard to substrate preference, murine and human cell 
ACSL4 utilizes AA and eicosapentaenoic acid with marked preference over all other fatty 
acids, indicating a critical function in AA metabolism [53, 54]. 
 ACSL5 is the only ACSL located in the outer mitochondrial membrane, 
suggesting a preferential role in activating acyl groups for mitochondrial β-oxidation. 
ACSL5 is highly expressed in small intestine, and to a lesser extent in liver, and uses a 
wide range of saturated and unsaturated fatty acids [55].  
Together with ACSL3, ACSL6 is the major ACSL expressed in brain. Murine and 
human ACSL6 show a clear preference for docosahexaenoic acid (22:6) and AA [56, 57]. 
The fact that this isoform presents a preference for the most abundant polyunsaturated 
fatty acids in brain suggests an important role in the synthesis of lipids in neuronal 
membranes, which experience a rapid phospholipid turnover. In addition, ACSL6 is also 
present in the plasma membrane of mature erythrocytes, where it activates long-chain 
fatty acids for remodeling of lipids and acylation of proteins [58]. 
In addition to the differences in fatty acid preference, subcellular location and 
tissue distribution, ACSLs also show different responsiveness to pharmacological 
inhibitors. It has been shown that ACSL1, ACSL3 and ACSL4 are sensitive to triacsin C, 
while ACSL5 and ACSL6 activity are not [51, 56, 59]. Moreover, thiazolidinediones, a 
type of oral insulin-sensitizing agents formerly used to treat type 2 diabetes, can 
specifically inhibit the activity of ACSL4 [56, 60]. The initial experiments with these 
inhibitors suggest that the various ACSL isoforms can drive acyl-CoAs to different lipid 
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metabolism pathways with some selectivity. It was described in human fibroblasts that 
triacsin C inhibits the de novo synthesis of diacylglycerol, triacylglycerol, cholesterol 
esters and phospholipids from glycerol but not the reacylation of fatty acids into 
phospholipids [61]. These findings have led to the suggestion that triacsin C-sensitive 
ACSLs supply acyl-CoA for the de novo synthesis of  glycerolipids, whereas isoforms 
resistant to triacsin C would be involved in reacylation of phospholipids and β-oxidation.  
Studies in human monocyte-derived macrophages have indicated that 
rosiglitazone, a type of thiazolidinedione, inhibits the incorporation of oleic acid into 
diacylglycerol and triacylglycerol, but not into phospholipids, whereas triacsin C inhibits 
the partitioning of these fatty acids into all lipid classes [60]. These data confirm a role 
for ACSL4 in the partitioning of fatty acids into diacylglycerol and triacylglycerol, and 
suggest additional roles for ACSL1 and ACSL3. On the other hand, studies in rat 
demonstrate that ACSL5, a triacsin C-resistant form, is also implicated in activating acyl-
CoA for the de novo synthesis of triacylglycerol [62].  
 
2.3. Lysophospholipid Acyltransferases 
Mammalian cells contain a number lysophospholipid acyltransferases that exhibit distinct 
acyl-CoA and lysophospholipid acceptor specificities. The recent availability of genomic 
information and sequence data has led to the identification of many lysophospholipid 
acyltransferases that may potentially be involved in AA recycling, either specifically or 
as part of a general function in homeostatic phospholipid metabolism. 
Two families of lysophospholipid acyltransferase enzymes have been recognized, 
namely the membrane bound O-acyltransferase (MBOAT) family, and the 1-acyl-
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glycerol-3-phosphate O-acyltransferase (AGPAT) family. [63-65]. While the MBOAT 
family comprises members specifically involved in the Lands cycle of phospholipid fatty 
acid remodeling, members of the AGPAT family are typically involved in the de novo 
pathway for phospholipid biosynthesis, but some members may also be involved in 
remodeling reactions. 
The MBOAT family includes acyltransferases that can use not only 
lysophospholipids as acceptors, but also diacylglycerol, cholesterol or even a protein [63-
65]. Only the MBOAT enzymes using lysophospholipids as acceptors will be considered 
in this review. Characteristic features of the MBOAT lysophospholipid acyltransferases 
include the existence of several membrane-spanning domains and a conserved His 
residue in a hydrophobic region that could constitute the catalytic site [66].  
Members of the AGPAT family were first hypothesized to utilize lysoPA 
specifically as acceptor, and thus were classified as acyltransferases of the de novo 
phospholipid biosynthetic pathway. It was realized later that these enzymes possess 
broader substrate specificity being able to utilize other lysophospholipids such as lysoPC 
and lysoPE. Common structural features of AGPAT acyltransferases include the presence 
of four conserved domains (motifs I-IV) that are important for catalytic activity and 
substrate binding  [67, 68].  
 
2.3.1. Acyltransferases using lysoPA as acceptor 
Three lysoPA acyltransferases have been cloned and characterized, namely LPAAT1 [69-
71], LPAAT2 [69, 72] and LPAAT3 [73]. LPAAT1 and LPAAT2 may utilize several 
acyl-CoA as donors [74], and are expressed in a wide number of tissues. LPAAT3 shows 
 13
selectivity for AA and, interestingly, also possesses LPIAT activity [73]. 
 
2.3.2. Acyltransferases using lysoPC as acceptor   
To date, three enzymes, called LPCAT1, LPCAT2, and LPCAT3 have found to utilize 
preferentially lysoPC as acceptor. LPCAT1 (also known as AGPAT9) [63, 64] was 
identified and characterized independently by two different groups in murine alveolar 
type II cells [75, 76]. LPCAT1 is highly expressed in lung, where it is suggested to play 
an important role in the synthesis of surfactant phospholipids, particularly dipalmitoyl 
glycerophosphocholine, the major component of pulmonary surfactant. Activity assays 
show high  selectivity for medium-chain saturated acyl-CoAs  (6:0-16:0) and lysoPC 
substrates, although the enzyme also displays significant activity towards lysoPA and 
lysoPG [76]. LPCAT1 appears to play an important role in the remodeling of PC in 
erythrocytes [77]. Recently it has been described that LPCAT1 is implicated in platelet-
activating factor synthesis under Ca2+ independent, non-inflammatory conditions [78]. 
Human LPCAT1 is also abundant in lung, and it seems to have the same properties as 
mouse LPCAT1. Other authors have described upregulation of human LPCAT1 in 
colorectal cancer adenocarcinomas. [79]. 
LPCAT2 has recently been cloned and characterized in mouse,  and is believed to 
constitute the main enzyme involved in the formation of platelet-activating factor under 
inflammatory conditions [80]. The enzyme belongs to the AGPAT family, and is highly 
expressed in inflammatory cells, mainly in resident macrophages and casein-induced 
neutrophils. It shows marked preference for lysoPC. Using RAW264.7 cells 
overexpressing LPCAT2, it was found that under resting cell conditions the enzyme 
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shows activity for acetyl-CoA and, strikingly, for arachidonoyl-CoA. Under these 
conditions, the enzyme appears to have more affinity for arachidonoyl-CoA than for 
acetyl-CoA. However, upon receptor stimulation the acetyltransferase activity of 
LPCAT2 was found to be significantly increased, while the arachidonoyl-CoA 
acyltransferase was not [80]. 
LPCAT3, also known as MBOAT5, is expressed at high levels in all murine 
tissues, especially testis [81]. The enzyme shows selectivity for lysoPC, although it can 
also utilize lysoPE and lysoPS. As for fatty acyl donors, the enzyme utilizes AA and 
linoleic acid with preference over other fatty acids [81]. In humans, the enzyme is 
expressed at high levels in liver, pancreas and adipose tissue. In terms of specificity a 
preference for linoleic acid over AA was noted [82, 83]. 
 
2.3.3. Acyltransferases using lysoPE as acceptor 
To date, three different LPEAT acyltransferases have been found, designated as LPEAT1 
(also known as MBOAT1), LPEAT2 (also known as AGPAT7), and MBOAT2. LPEAT1 
was extensively characterized in mouse and exhibits preference for oleoyl-CoA. The 
enzyme can also utilize lysoPS as an acceptor, although lysoPE is the preferred substrate 
[81]. The human enzyme displays similar properties, although in this case a higher 
preference for lysoPS over lysoPE was found [83]. 
LPEAT2 was identified in human tissues by Cao et al [84]. The enzyme is highly 
expressed in brain and inflammatory cells. It has selectivity for long-saturated acyl-CoAs 
as donors (16:0, 18:0, 18:1) and shows selectivity towards lysoPE, although the enzyme 
can also utilize lysoPC, lysoPG and lysoPS. Because of the brain is a tissue highly 
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enriched in PE, LPEAT2 has been suggested as a crucial enzyme in PE remodeling, and 
it could be implicated in neurological disorders, like Alzheimer or multiple sclerosis.  
 MBOAT2 has been extensively characterized in mice, and is highly expressed in 
epididymis, brain, testis and ovary and it shows preference for oleyl-CoA as donor and 
can use both lysoPE and lysoPC as acceptors. Human MBOAT2 has clearly been shown 
to exhibit preference for lysoPE over lysoPC, and also for oleoyl-CoA [82]. Mouse 
MBOAT2 has also been called LPCAT4, because it utilizes lysoPC and lysoPE equally 
well [81]. 
 
2.3.4. Acyltransferases using lysoPI as acceptor  
MBOAT7 was identified in C. elegans as an acyltransferase specific for lysoPI [85]. In 
addition, MBOAT7 exhibits high selectivity for AA and eicosapentaenoic acid, making it 
an obvious candidate for mediating AA recycling into PI via the Lands pathway. The 
homolog in humans is also called BB1/LENG4, and displays the same substrate 
specificity as the C. elegans enzyme [82].  
The one other LPIAT described to date is LPAAT3 which, as indicated above, 
may utilize either lysoPA or lysoPI as acceptors [73]. 
 
2.3.5. Other lysophospholipid acyltransferases 
LCLAT1, cloned in mice, is involved in the remodeling of cardiolipin, a 
glycerophospholipid abundant in mitochondria [86]. LCLAT1 possesses both acyl-
CoA:monolysocardiolipin acyltransferase and acyl-CoA:dilysocardiolipin acyltransferase 
activities, and uses oleic and linoleic acids with preference as donors. 
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LPGAT1 was identified in human as an acyltransferase using PG as acceptor [87] 
PG is a major component of lung surfactant; thus LPGAT1 is presumed to play an 
important key role in lung physiology. The enzyme appears to show some selectivity for 
palmitic, stearic, and oleic acids. 
 
3. Role of PLA2 in AA Mobilization 
Stimulation of cells via receptor agonists frequently results in the activation of 
phospholipid hydrolysis by phospholipase A2 enzymes. An immediate consequence of 
this is the net accumulation of free AA that can be used for various cellular functions, e.g. 
the biosynthesis of eicosanoids. Various routes for AA release have been described, 
including a phospholipase C/diacylglycerol lipase pathway or the inhibition of 
phospholipid AA reacylation; however, there is general agreement that the PLA2-
mediated hydrolysis of phospholipids is the major pathway controlling AA mobilization 
in stimulated cells, and that all major AA-containing phospholipid classes, namely PC, 
PE, and PI contribute to this release [88-91]. 
 Mammalian cells contain multiple structurally diverse  PLA2 enzymes capable of 
hydrolyzing sn-2 fatty acids from phospholipids. PLA2s have been systematically 
classified according to their nucleotide sequence. In the latest update to this classification, 
the PLA2 enzymes were classified into fifteen group types, according to their primary 
sequence [92]. Additionally, a sixteenth PLA2 group has been reported very recently [93]. 
However, a second classification of the PLA2 enzymes, sometimes more useful, also 
exists which categorizes the enzymes into five major families attending to biochemical 
commonalities [89, 94]. These families are the Ca2+-dependent secreted enzymes, the 
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Ca2+-dependent cytosolic enzymes, the Ca2+-independent cytosolic enzymes, the platelet-
activating factor acetyl hydrolases, and the lysosomal PLA2s. Of these families, the two 
first ones have been repeatedly implicated in AA mobilization in response to a variety of 
immunoinflammatory stimuli [88, 89, 95]. Today, it is firmly established that the 
calcium-dependent cytosolic group IVA PLA2α (cPLA2α) is the critical enzyme in AA 
release [96] and that, depending on cell type and stimulation conditions, a secreted PLA2 
—in particular that belonging to groups IIA, V and X— may also participate by 
amplifying the cPLA2α-regulated response [17, 97-100]. In addition, recent data have 
also indicated that the Ca2+-independent cytosolic PLA2 (group VI enzymes) can also 
mediate AA release under certain conditions [101, 102].  
A number of excellent reviews have recently been published covering various 
aspects of cPLA2α biochemistry, including structure, catalysis, regulation by Ca2+ 
availability, and physiological/pathophysiological functions [96, 102-106]. Thus, in the 
following sections we will focus on recent data on the cellular regulation of cPLA2α by 
phosphorylation and anionic lipids. 
 
 
3.1. Role of phosphorylation reactions in regulating cPLA2α activity in cells 
cPLA2α can be phosphorylated on multiple residues under activation conditions, but only 
three of them, Ser505, Ser727, and Ser707 appear to be relevant to the regulation of AA 
mobilization in agonist-stimulated cells [107-109]. Phosphorylation of cPLA2α at these 
sites only modestly increases the activity of the enzyme in vitro, thus suggesting that  
such phosphorylation serves other regulatory functions in cells. 
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 Phosphorylation of cPLA2α at Ser505 was the first to be described [107], and still 
is the most extensively studied, and perhaps the most controversial from a functional 
point of view. Phosphorylation of cPLA2α  at Ser505  stably increases enzyme activity by 
1.5-2-fold, and promotes a significant mobility shift of the protein in acrylamide gels 
[107]. Depending on cell type and stimulus, the phosphorylation reaction is catalyzed by 
extracellular-regulated kinases p42 and p48 [107], p38 [110] and SAPK/JNK [111, 112]. 
By studying in vitro membrane affinity of different phosphorylation-site mutants of 
cPLA2α, Cho and colleagues [113] have recently described that mutation at Ser505 results 
in a lower affinity for PC membranes than the wild type enzyme, which is due to a faster 
desortion from the membrane. This difference is very much enhanced at low Ca2+ 
concentrations compared with high Ca2+ concentrations during the assays (2.5 and 50 μM 
respectively) [113]. In experiments with cells, this different behavior can also be 
observed at low intracellular Ca2+ concentrations during cellular activation, a situation 
that is observed when the cells are stimulated with 2 μM Ca2+ ionophore (0.4 mM 
intracellular Ca2+). The interpretation of these results is that phosphorylation at Ser505 
enhances hydrophobic interaction of the enzyme with the membrane, by promoting 
membrane penetration of the hydrophobic residues Ile399, Leu400, and Leu552. This effect 
probably occurs through a conformational change of the protein [113]. Other studies, 
however, have not found differences between the membrane translocation behavior of the 
wild type enzyme and the mutated enzyme in Ser505 [114, 115]. Recently, it has been 
described that in lung fibroblasts activated with phorbol esters or serum, Ser505 
phosphorylation does not work to lower the Ca2+ threshold levels necessary for cPLA2α  
translocation, but only acts to increase  the catalytic activity of the enzyme [116].  
 19
 cPLA2α phosphorylation at Ser727 was first described in Sf9 cells overexpressing 
cPLA2α [108], and later in agonist-stimulated human platelets [111]. In platelets, this 
phosphorylation is required for a full AA mobilization response, and the kinase involved 
appears to be MNK-1 or a closely related kinase [117]. Phosphorylation of cPLA2α at 
Ser727 increases the cellular activity of the enzyme by a mechanism that is not mediated 
by increased membrane affinity [117] but by a mechanism related with the interaction of 
cPLA2α with a tetramer of p11 and annexin 2A in the cytosol [118]. In vitro activity 
assays and membrane binding measurements by surface plasmon resonance analyses 
showed that, in resting conditions cPLA2α interacts with a tetramer of p11 and annexin 
2A via the hydroxyl group of Ser727, inhibiting the targeting of the enzyme to cellular 
membranes and the AA release. When cells are stimulated and phosphorylation in Ser727 
occurs, the tetramer is displaced from cPLA2α and the enzyme can then interact with 
cellular membranes and effect phospholipid hydrolysis [118].  This mechanism has yet to 
be confirmed  in agonist-stimulated cells. 
Phosphorylation of cPLA2α on Ser515 was first described as the only residue 
phosphorylated by calcium/calmodulin-dependent protein kinase II  in vitro,  and leads to 
an increase in enzymatic activity of about two-fold [109]. The biological role of this 
phosphorylation has been defined very recently in norepinephrine-stimulated vascular 
smooth muscle cells, by using a specific antibody against the phosphorylated residue 
[119]. Phosphorylation of cPLA2α at Ser515 by calcium-/calmodulin-dependent protein 
kinase II appears to be a pre-requisite for the further phosphorylation of the enzyme at 
Ser505 by ERK1/2, and both phosphorylated sites are required for a full AA mobilization 
response to response to norepinephrine. In this system, mutation of Ser505, Ser515 or both 
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(Ser505/515) to Ala does not change the ability of the mutated enzyme to translocate to the 
nuclear envelope [119].  
 
3.2. Cellular Regulation of cPLA2α by anionic phospholipids 
The activating effect of anionic phospholipids on cPLA2α was first described by Leslie 
and Channon [120] in studies utilizing a partially purified enzyme from RAW264.7 cells. 
It was shown that PS, PA, PI and phosphatidylinositol-4,5-bisphosphate (PIP2) have the 
capability to increase cPLA2α activity in vitro when incorporated into the vesicle 
substrate. PIP2 was the best activator, reaching a 7-fold increase in activity at 1 mol%  
[120]. This effect could be further enhanced to 20-fold by coincubating with 
diacylglycerol or PE, decreasing at the same time the requirement of Ca2+ for enzyme 
activity from mM to nM [120].  
The activating effects of PIP2 were later confirmed by Mosior and colleagues  
PIP2 utilizing human recombinant cPLA2α [121]. Binding of cPLA2α to large unilamellar 
vesicles of PC was enhanced 20-fold in the presence of 1% PIP2, with a concomitant 
increase in activity of the same magnitude. The stoichiometry of binding was 1:1, and 
just 1 molecule per 2000 lipid molecules in the membranes was enough to double the 
binding of the cPLA2α [121]. The binding effect produced by PIP2 was so important that 
it supported measurable association with vesicles and activity even in the absence of Ca2+ 
in the reaction mixture (presence of EGTA). Other related phospholipids like PI(3,4,5)P3 
and PI(3,4)P2 also enhanced PLA2α activity in their assay but at 60 and 63% of the PIP2. 
However,  other anionic lipids such as PI, PS or PA had little or opposite effects on the 
binding of cPLA2α to the lipid vesicles [121]. Following on these observations, Das and 
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Cho [122] identified a polybasic cluster in the catalytic domain of cPLA2α that, at least 
partially, accounted for PIP2 binding (Lys541, Lys543, Lys544, and Arg/Lys488). Mutations 
of this cluster eliminate the specific activation of the cPLA2α promoted by PIP2. 
However, no effect of PIP2 on the affinity of the enzyme for vesicles was appreciated in 
experiments of surface plasmon resonance [122].  
In a cellular context, the first evidence for the regulation of cPLA2α by PIP2 was 
obtained in a macrophage-like cell line activated by UV radiation [123]. Inhibition of 
phosphoinositide increases during cellular activation also inhibited the release of AA. 
The biological relevance of these observations was that UV activated cPLA2α in the cells 
in the absence of any apparent change in the intracellular Ca2+ concentration [123]. In 
this regard, Das and Cho also observed that sequestration of cellular PIP2 by over-
expressing a pleckstrin homology domain of the phospholipase C-δ1, considerably 
decreased the amount of AA released by cellular activation with ionophore [122]. Later it 
was also demonstrated that exogenous PIP2 shuttled into the cells by coupling it to 
cationic carriers, promoted the translocation of cPLA2α to those membranes were PIP2 
was localized, mainly perinuclear membranes [124]. The effect was observed at basal 
intracellular Ca2+ concentrations (50 nM), but it did not occur in the presence of EGTA, 
suggesting that the process of cPLA2α translocation by PIP2 is not Ca2+-independent. In 
support of this, a mutant in the Ca2+ binding site of the enzyme (D43N) did not 
translocated in response to PIP2 [124]. It was also observed that intracellular increases in 
PIP2 lowered the Ca2+ requirements for enzyme translocation to intracellular basal levels. 
Furthermore, mutations in the cationic cluster Lys541, Lys543, Lys544, and Lys488 did not 
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change the translocation pattern of the enzyme to intracellular membranes but inhibited 
the release of AA, indicating a non-productive membrane binding [124].   
In contrast with these observations, by using yeast-based assay that tests the 
ability of proteins to bind to membrane lipids, Le Berre and colleagues [125] have found 
that only the Ca2+-binding domain of cPLA2α interacts with lipids, including PIP2. 
Because inhibitory effects on cPLA2α activity were observed by overexpressing the 
pleckstrin homology domain of PLCδ1, and PIP2-specific 5’-phosphatase in stimulated 
cells, the conclusion was made that cPLA2α activity can be modulated by sequestration 
or depletion of cellular PIP2, but not by direct binding [125].  
Another anionic phospholipid that appears to have profound effects on the activity 
and physical state of cPLA2α is ceramide 1-phosphate. Chalfant and colleagues 
demonstrated that ceramide kinase and its product ceramide 1-phosphate mediated the 
activation of cPLA2α  during cellular stimulation with IL-1 or calcium ionophore [126].  
It was also observed that ceramide 1-phosphate induces the translocation of cPLA2α to 
intracellular membranes, mainly Golgi and perinuclear membranes [127]. Moreover, the 
C2 domain of the enzyme itself also translocated in response to ceramide 1-phosphate. In 
vitro studies demonstrated that ceramide 1-phosphate binds cPLA2α through the C2 
domain (at the cationic β-groove Arg57, Lys58, Arg59) and that such an interaction 
increases the enzymatic activity in a calcium-dependent manner [127, 128]. By using 
surface-dilution kinetics and surface plasmon resonance it has been described as well that 
ceramide 1-phosphate activates cPLA2α not by affecting the Michaelis-Menten constant, 
but by increasing the residence time of the enzyme on membranes, decreasing the 
dissociation constant of the enzyme to membrane PC [129, 130].  
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3.3. sPLA2 Role in AA Release  
There is much data suggesting that certain sPLA2 form are involved in mediating AA 
mobilization in a variety of cells, most notably those involved in immunoinflammatory 
reactions, like macrophages and mast cells [89, 94]. However, the mode how sPLA2 
participates in this process is still a very controversial issue. This is due in part to the fact 
that most of the evidence implicating sPLA2 in AA mobilization derives from studies 
utilizing exogenous enzymes or cells overexpressing certain sPLA2 forms, and limited 
information is available on the role of the “endogenous” relevant sPLA2.   
Exogenous sPLA2, particularly that belonging to Groups IIA, V, and X, or sPLA2 
over-expressed in various cells can amplify the essential role of cPLA2α in eicosanoid 
biosynthesis by augmenting the release of AA and other fatty acids under various 
experimental conditions [98, 131-135]. The sPLA2 enzymes could potentially be involved 
in the cPLA2α-dependent AA mobilization through three pathways, one involving re-
internalization via caveolin-rich domains [136, 137], the second involving direct 
interaction with PC-rich outer membrane domains [136, 138, 139], and the third one 
involving an undefined intracellular action prior secretion of the enzyme [140]. 
Nonetheless, sPLA2s may also act to release AA in a cPLA2α-independent manner, as 
demonstrated by studies in cells from mice lacking cPLA2α by genetic disruption [141]. 
Regarding the endogenous enzyme, studies using mice in which the gene 
encoding group V sPLA2 was deleted have provided conclusive evidence for the role of 
this enzyme in eicosanoid production by macrophages and mast cells in vivo [142]. 
Interestingly, the effect of  sPLA2 is observed in cells on a C57BL/6 genetic background, 
while in cells on a BALB/c background no sPLA2 effect could be ascertained [143]. 
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These data provide evidence that two different phenotypes may exist in cells regarding 
the involvement of sPLA2 in eicosanoid generation. Whether these two phenotypes may 
also manifest in cells depending on culture conditions is unknown at present.  
 On the other hand, studies on the role of sPLA2 in AA release are complicated by 
the existence of cross-talk between the sPLA2 and the main effector of the response, the 
cPLA2α. This cross-talk may work in both directions, i.e. cPLA2α may regulate the 
action of sPLA2 or vice versa.  
In some cell types such as human and murine macrophage-like cell lines, cPLA2α 
has been shown to regulate sPLA2 activity by a mechanism involving the rapid 
generation of hydroperoxyeicosatetraenoic acid [144, 145]. At long incubation times, 
activation of  cPLA2α is also required for the increased expression of group V sPLA2 that 
is characteristically induced by immunoinflammatory stimuli such as lipopolysaccharide 
and, as with the short-term response, may involve the production of 
hydroperoxyeicosatetraenoic acid [146-150] . 
The regulation of cPLA2α by sPLA2 has been characterized in detail in some 
instances. In murine mesangial cells, an adenoviral infection technique was used to stably 
express group IIA and/or group V sPLA2 into the cells [100]. cPLA2α was found to effect 
the AA release and, when present, both sPLA2 forms amplified the cPLA2α-mediated 
response, this resulting in increased AA mobilization [100]. Moreover, a correlation was 
found to exist between the expression level of cPLA2α and the magnitude of AA release. 
Such a correlation did not occur between the expression level of sPLA2 and the extent of 
AA release. Recent work in mouse mast cells from mice lacking group V sPLA2 by 
genetic deletion has provided conclusive evidence that sPLA2 modulates the activity of 
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cPLA2α by regulating its phosphorylation via extracellular-regulated kinases [151]. 
Utilizing inhibitors, similar observations have also been made in recent work with murine 
macrophage-like cells [152, 153]. 
  
3.4. iPLA2 Role in AA Release 
The group VIA PLA2 (iPLA2-VIA) is ubiquitously expressed and has the potential to 
participate in AA release under some conditions [101, 102]. However, the role of this 
enzyme in AA release has traditionally been inferred from studies using the inhibitor 
BEL, a compound that manifests high selectivity for iPLA2 in vitro but not in vivo [154-
156]. In some studies, BEL was found to inhibit the AA release, but in others, notably in 
phagocytes, no significant effect was detected [89]. It appears likely that the involvement 
of group iPLA2-VIA in AA release is markedly cell- and stimulus-dependent, as most of 
the roles attributed to this enzyme in cell physiology appear to be [22, 101, 157]. Since 
various iPLA2–VIA splice variants co-exist in cells [22, 101, 157], it is possible that the 
enzyme is subject to multiple regulatory mechanisms that differ among cell types and 
stimulation conditions. This in turn could also explain the multiplicity of functions that 
this enzyme appears to serve depending on cell type. 
 Recently, mice with targeted disruption of the gene encoding for iPLA2–VIA have 
been generated [158]. Use of cells from these animals has reinforced the idea that the 
involvement of iPLA2 in AA mobilization notably differs depending on cell type and 
stimulation conditions. Thus, peritoneal macrophages from iPLA2–VIA null mice appear 
to release AA in response to zymosan in a manner that is indistinguishable from that of 
cells from wild type animals [159]. In contrast however, iPLA2–VIA appears to be 
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crucial for AA mobilization in macrophages upon free cholesterol loading [159] and for 
the eicosanoid response of macrophages stimulated via class A scavenger receptors [160]. 
 
4. Conclusions 
In the last two decades much effort has been made to elucidate the mechanisms by which 
AA is liberated and incorporated into phospholipids. This review has dealt with the 
relatively high number of enzymes with acyl-CoA synthetase, CoA-dependent 
acyltransferase or phospholipase A2 activities that have been described to participate in 
the regulation of cellular AA availability. Some of these enzymes show a marked 
selectivity for AA. Clearly, this is a very complex issue involving multiple enzymes and 
pathways, and there is still much to be learned about the interplay between some of the 
AA-utilizing enzymes and the regulatory mechanisms involved. 
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Figure Legends 
 
Figure 1.  Pathways for the incorporation of arachidonic acid into glycerolipids. LPLAT, 
lysophospholipid acyl-CoA acyltransferase. 
 
Figure 2. Arachidonic acid incorporation into and remodeling among phospholipids. 
Adapted with permission from ref. 15 (© The Biochemical Society).  
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